￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How effective is the "legendary broad-spectrum" anti-cancer drug larotrectinib? The objective response rate is as high as 75%!

2025-10-19 11:44:20

Check Details
Focusing on anti-tumor small molecule drugs, Yuanyuankang’s EGFR/HER2 inhibitor TY-4028 has been approved for clinical use in the United States

2025-10-19 11:44:20

Check Details
CSPC Pharmaceutical Group: Antibody-drug conjugate CPO301 obtained FDA clinical trial approval

2025-10-19 11:44:20

Check Details
What is the effect of nivolumab on lung cancer

2025-10-19 11:44:20

Check Details
Focus on NSCLC, AstraZeneca’s ADC new drug submits clinical application in China

2025-10-19 11:44:20

Check Details
Contraindications for taking nivolumab

2025-10-19 11:44:20

Check Details
How often should you lose nivolumab

2025-10-19 11:44:20

Check Details
Conditional activation blocks VISTA to inhibit solid tumors, and the US FDA approves the new drug research application of SNS-101

2025-10-19 11:44:20

Check Details
Acting on the tumor microenvironment, Parthenon announced that the self-developed drug PRTH-101 has completed the first patient administration in the phase I clinical trial

2025-10-19 11:44:20

Check Details
Innovent Biologics/Eli Lilly's RET inhibitor "Seputinib" is officially commercialized in China_Canghule

2025-10-19 11:44:20

Check Details
Express delivery! Novartis c-Met inhibitor "capmatinib" applies for marketing in China

2025-10-19 11:44:20

Check Details
The efficacy of nivolumab in treating gastric cancer: is it an immune drug or a targeted drug?

2025-10-19 11:44:20

Check Details
Category
相关知识